Correlation of pituitary histomorphometry with dopamine and dopamine D2 receptor expression in horses with pituitary pars intermedia dysfunction.

This study investigates the correlation between pituitary gland abnormalities, and the expression of dopamine and dopamine D2 receptors in horses suffering from pituitary pars intermedia dysfunction (PPID). The findings suggest that decreased dopamine in these horses contributes to cell overgrowth in a region of the pituitary gland, and that doping D2 receptors could be an effective treatment.

Background and Objective

• This research aims to clarify whether decreased dopamine (a type of neurotransmitter) or dysfunction of dopamine D2 receptors (D2r) causes PPID, a common disorder in aging horses characterized by endocrine system malfunction.
• The scholars note that while previous studies have highlighted neurodegeneration leading to decreased dopamine in the PI and increased pro-opiomelanocortin-derived peptides in the bloodstream, it’s unclear whether this decrease in dopamine or D2r dysfunction is the primary contributor to PPID.

Methodology

• To examine this further, the researchers collected and examined 28 retrospective cases of horses with PPID.
• They graded these cases and determined the expression of tyrosine hydroxylase (TH, an enzyme that plays a critical role in dopamine production), and D2r in the PI.

Findings

• The histological and immunohistochemical analysis revealed that horses with higher tumor histological grades (indicating more severe disease) had reduced TH expression along with increased D2r immunoreactivity in the PI.
• The correlation between these findings supports the theory that Dopamine plays a significant role in controlling the proliferation of neoplastic (abnormal) cells in the PI.
• The increased Dopamine D2 receptor expression possibly suggests a compensatory response to decreased dopamine levels.

Conclusions

• Based on the correlated decrease of dopamine production and the increase of D2r in the pituitary gland, the researchers conclude that decreased dopamine could be a driving factor in the development of PPID.
• This indicates that D2r agonists (compounds that activate D2r) may be an effective treatment for PPID, offering potential new avenues for managing the condition in horses.